List of SBIR/STTR awards granted to GlycoT Therapeutics
GlycoT TherapeuticsName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to GlycoT Therapeutics in August, 2019 for $150,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM134816-01 | Phase I | 150,000 | August 1, 2019 | |||||||
A SBIR Phase I contract was awarded to GlycoT Therapeutics in May, 2022 for $231,535.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM146537-01 | Phase I | 231,535 | May 1, 2022 | |||||||
A SBIR Phase I contract was awarded to GlycoT Therapeutics in April, 2018 for $292,823.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43GM128547-01 | Phase I | 292,823 | April 1, 2018 | |||||||
A SBIR Phase II contract was awarded to GlycoT Therapeutics in April, 2019 for $714,065.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44GM123823-02A1 | Phase II | 714,065 | April 5, 2019 | |||||||
A SBIR Phase II contract was awarded to GlycoT Therapeutics in August, 2021 for $774,934.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44GM134816-03 | Phase II | 774,934 | August 1, 2021 | |||||||
A SBIR Phase I contract was awarded to GlycoT Therapeutics in August, 2017 for $218,846.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43GM123823-01A1 | Phase I | 218,846 | August 1, 2017 |
